Table 1.
−r/rLBCL patient demographic and clinical characteristics
| Characteristic | CAR19 Discovery cohort, N = 65 | CAR19 Validation cohort, N = 73 |
|---|---|---|
|
| ||
| Outcome | ||
|
| ||
| Ongoing Response | 29 (45%) | 31 (42%) |
| Progression | 36 (55%) | 42 (58%) |
| Follow-up, months; median (95% CI) | 36.9 (30.4–40.8) | 23.2 (17.4 - NA) |
| Age | 58 (49, 68) | 63 (58, 72) |
|
| ||
| Sex | ||
|
| ||
| Female | 22 (34%) | 37 (51%) |
| Male | 43 (66%) | 36 (49%) |
|
| ||
| Histology | ||
|
| ||
| DLBCL | 35 (54%) | 37 (51%) |
| HGBCL | 9 (14%) | 11 (15%) |
| PMBCL | 3 (4.6%) | 3 (4.1%) |
| TFL | 18 (28%) | 21 (29%) |
| THRLBCL | 0 (0%) | 1 (1.4%) |
|
| ||
| Stagea | ||
|
| ||
| 1 | 6 (9.4%) | 15 (21%) |
| 2 | 7 (11%) | 13 (18%) |
| 3 | 6 (9.4%) | 8 (11%) |
| 4 | 45 (70%) | 36 (50%) |
|
| ||
| IPIa | ||
|
| ||
| 0–1 | 18 (28%) | 17 (24%) |
| 2 | 16 (25%) | 24 (33%) |
| 3 | 21 (32%) | 22 (31%) |
| 4–5 | 10 (15%) | 9 (12%) |
|
| ||
| Prior lines of therapy | ||
|
| ||
| 0–1 | 0 (0%) | 0 (0%) |
| 2 | 27 (42%) | 25 (34%) |
| 3 | 18 (28%) | 22 (30%) |
| 4 | 15 (23%) | 18 (25%) |
| 5 or more | 5 (7.7%) | 8 (11%) |
| Prior Auto SCT | 13 (20%) | 19 (26%) |
Median (IQR); n (%).
Stage and IPI reported when available.
DLBCL, diffuse large B cell lymphoma; HGBCL, high-grade B cell lymphoma; TFL, transformed follicular lymphoma; PMBCL, primary mediastinal B cell lymphoma; THRLBCL, T cell/histiocyte-rich large B cell lymphoma.
a
Relapsed/refractory stage and IPI established prior to CAR19 therapy.